BNET Industries
Last Fiscal Year Sales:$124.6M
- Public
- US
Dow Jones Description
The Company manufactures and markets a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases. Bentley's drug delivery technology is focused on improving the delivery of pharmaceuticals and peptides through a broad range of proprietary drug delivery technologies.
Chairman of the Nominating and Governance Committee
John W. SpiegelNumber of Employees 470
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Teva says higher dose of multiple sclerosis drug shows no increased efficacy - Update
-
Movers: Schering-Plough, Merck, Fairpoint, Ansoft, Citigroup, IACI
-
Teva to Acquire Bentley Pharmaceuticals
-
Bentley Pharmaceuticals Reports Third Quarter 2006 Results
-
Bentley Pharmaceuticals Names Richard P. Lindsay Vice President and CFO
News & Analysis
Filter by
bentley pharmaceuticals inc. and finance and sec - All News and Analysis
Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock
EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT) ("Bentley" or the "Company") announced today that it notified the New York Stock Exchange (the "NYSE") of its intent to delist its common stock, par value $0.02 per share, from the NYSE immediately following the consummation of the transactions contemplated by the...
Bentley Pharmaceuticals & Teva Pharmaceutical Industries Ltd. Merger Consideration Established at $14.82 Per Share
EXETER, N.H. -- Bentley Pharmaceuticals, Inc. ("Bentley") (NYSE: BNT) announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd. ("Teva") has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, CPEX Pharmaceuticals, Inc....
Bentley Board Approves Spin-off of Drug Delivery Business
Bentley Sets July 22, 2008 as Date for Stockholders to Vote on Proposed Acquisition by Teva Pharmaceutical Industries Ltd. EXETER, N.H. -- The board of directors of Bentley Pharmaceuticals, Inc. (NYSE: BNT) today approved the spin-off of its drug delivery business into a new publicly traded company to be...
Bentley Pharmaceuticals Announces First Quarter Financial Results
Reports Revenues of $40.0 Million in the First Quarter; Revenues Increase 27% over 2007 First Quarter EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today reported financial results for the first quarter and three months ended March 31, 2008. First quarter 2008 revenues...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Lane Bassett Hunt | President |
| Jim Buckley | Executive Vice President |
| Elaine Melia | Director, Finance |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| John W. Spiegel | Chairman of the Nominating and Governance Committee |
| Edward J. Robinson | Chairman |
| F. Ross Johnson | Chairman and Chief Executive Officer of Rjm Group |
| Michael McGovern | Vice Chairman and Director |
| Miguel Fernandez | Chairman of the Compensation Committee |
| Adolfo Herrera | Board of Directors |
| Charles L Bolling | Board of Directors |
| Johm W. Spiegel | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| World Trade Center of Atlanta | Current | |
| Bentley Pharmaceuticals, Inc. | Chairman of the Nominating and Governance Committee | Current |
| Credisphere | Chairman of the Board | Current |
| S1 Corporation | Non-Executive Chairman | Current |
| Rock-Tenn Company | Chairman | Current |
| Children's Healthcare | Board of Directors | Current |
| Colonial Properties | Board Member | Current |
| Colonial Properties Trust | Board of Directors | Current |
| Creative Growth Group, Inc. | Board of Directors | Current |
| CPEX Pharmaceuticals Inc. | Director | Current |
| Fsb Solutions | Board of Directors | Current |
| S1 Enterprise | Board of Directors | Current |
| Bank Administration Institute | Board of Directors | Current |
| HBMC Holdings LLC | Board of Directors | Current |
| S1 Corporation | Board of Directors | Current |
| The Advisory Council | Board of Directors | Current |
| HomeBanc Corp. | Board of Directors | Current |
| Children's Healthcare | Trustee | Current |
| The Advisory Council | Member | Current |
| Bentley Pharmaceuticals, Inc. | Vice Chairman and Chief Financial Officer of Suntrust Banks, Inc. | Former |
| SunTrust Banks, Inc. | Chief Financial Officer | Former |
| SunTrust Banks, Inc. | Executive Vice President | Former |
| High Museum of Art | Former | |
| Bank Administration Institute | Chairman | Former |
| Bentley Pharmaceuticals, Inc. | Board of Directors | Former |
| Rock-Tenn Company | Board of Directors | Former |
| SunTrust Banks, Inc. | Vice Chairman | Former |
| SunTrust Banks, Inc. | Director | Former |
| Emory University | MBA | Former |
| Wabash College | Bachelor's Degree In Economics | Former |
Edward J. Robinson retired as Chief Operating Officer of Meditrust Operating Company, a healthcare REIT, in 1998. Previously he was President and Chief Operating Officer of Avon Products, Inc., a public beauty products company, from 1993 to 1997, and Executive Vice President and Chief Financial Officer of Avon Products, Inc. from 1989 to 1992. Previously, he held various positions with RJR Nabisco and its predecessor companies, Standard Brands and Nabisco Brands, including Executive Vice President, Chief Financial Officer, Vice President Treasurer and Senior Vice President Controller. Mr. Robinson serves on the board of directors of Medical Staffing Network Holdings, Inc. and also serves on the Advisory Board of W.R. Capital Management L.P. Mr. Robinson received a B.A. in Business Administration from Iona College. Mr. Robinson is a Certified Public Accountant licensed by the State of New York.
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Chairman | Current |
| Medical Staffing Network Holdings Inc. | Board of Directors | Current |
| Avon Products, Inc. | President | Former |
| Avon Products, Inc. | Executive Vice President and Chief Financial Officer | Former |
| Kraft Foods Inc. | Executive Vice President | Former |
| Iona College | B.A. In Business Administration | Former |
F. Ross Johnson has been the Chairman and Chief Executive Officer of RJM Group, a management advisory and investment firm, since 1989. Prior to 1989, Mr. Johnson was the President and Chief Executive Officer of RJR/Nabisco, Inc., an international consumer products company, having held various senior executive positions in RJR/Nabisco, Inc. and its predecessors, Standard Brands and Nabisco Brands since 1971. He received a Bachelor of Commerce from the University of Manitoba, Canada and a Master of Commerce from the University of Toronto, Canada. Mr. Johnson serves on the boards of directors of AuthentiDate Holding Corporation and EdgeStone Capital Partners and serves on the advisory boards of Power Corporation of Canada, Wachovia Bank Florida, Bennett Advisory Group Palm Beach and Black & McDonald Ltd.
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Chairman and Chief Executive Officer of Rjm Group | Current |
| Black & McDonald | Board of Directors | Current |
| EdgeStone Capital Partners Inc. | Board of Directors | Current |
| AuthentiDate Holding Corp. | Chair of Board | Former |
| University of Toronto | Master of Commerce | Former |
| Bentley Pharmaceuticals, Inc. | Board of Directors | Current |
| University of Manitoba | Bachelor of Commerce | Former |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | President | Current |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Executive Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Director, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Vice Chairman and Director | Current |
| Employment Technologies Corp | Vice Chairman of the Board | Current |
| CPEX Pharmaceuticals Inc. | Director | Current |
| Bentley Pharmaceuticals, Inc. | Board of Directors | Former |
| University of Illinois | Juris Doctor | Former |
| University of Illinois | M.S. In Accounting | Former |
| University of Illinois | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Chairman of the Compensation Committee | Current |
| CPEX Pharmaceuticals Inc. | Director | Current |
| GlaxoSmithKline Plc | Vice President for Latin America | Former |
| Bentley Pharmaceuticals, Inc. | Director | Current |
| The University of Western Ontario | M.B.A. | Former |
| University of British Columbia | Former |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Board of Directors | Current |
| Bentley Pharmaceuticals, Inc. | Managing Director | Current |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Bentley Pharmaceuticals, Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Schiff Nutrition International, Inc. F3Q10 (Qtr End 02/28/10) Earnings Call Transcript
on Mar 17, 2010about WNI
-
XOMA Ltd. Q4 2009 Earnings Call Transcript
on Mar 11, 2010about XOMA
-
Peregrine Pharmaceuticals, Inc. F3Q10 (Qtr End 01/31/10) Earnings Call Transcript
on Mar 11, 2010about PPHM
-
Mannatech, Incorporated Q4 2009 Earnings Call Transcript
on Mar 11, 2010about MTEX
-
Chelsea Therapeutics International, Ltd. Q4 2009 Earnings Call Transcript
on Mar 10, 2010about CHTP
IndustryTop Rated
- Efficacy of Roche's Flu Drug Tamiflu In Doubt 3 votes
- The 5 Worst Drug Companies of 2009 3 votes
- If Approved -- FDA Drug Labeling Could Decide Ultimate Success of MannKind's Afrezza 3 votes
- 2010 FDA Approvals Could Lead to Launch of Eight Blockbuster Biotech Drugs 3 votes
- Dumbest PowerPoint Ever? J&J's P&L Slideshow of Alleged Kickback Scheme 2 votes


